Ironwood Pharmaceuticals Inc (IRWD) stock
IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.78−0.09 (-1.85%)
Close on Nov 18, 2026Market cap $789.85MP/E 6.2Yield –
Ironwood Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ironwood Pharmaceuticals's price to sales ratio was 2.0× on Nov 10, 2026, against 1.7× a year earlier. Over the last 5 years it ranged from 0.3× to 5.1×, with a median of 2.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 2.0× | +0.4 |
| 2025 | Dec 31, 2025 | 1.6× | −0.3 |
| 2024 | Dec 31, 2024 | 1.9× | −2.3 |
| 2023 | Dec 29, 2023 | 4.1× | −0.4 |
| 2022 | Dec 30, 2022 | 4.5× | −0.1 |
| 2021 | Dec 31, 2021 | 4.6× | +0.0 |
| 2020 | Dec 31, 2020 | 4.6× | −0.3 |
| 2019 | Dec 31, 2019 | 4.8× | +2.7 |
| 2017 | Jan 31, 2017 | 2.1× | −0.1 |
| 2016 | Dec 30, 2016 | 2.3× | −6.9 |
| 2015 | Dec 31, 2015 | 9.1× | −37.5 |
| 2014 | Dec 31, 2014 | 46.6× | +25.3 |
| 2013 | Dec 31, 2013 | 21.3× | +13.7 |
| 2012 | Dec 31, 2012 | 7.6× | −16.0 |
| 2011 | Dec 30, 2011 | 23.6× | +21.4 |
| 2010 | Dec 31, 2010 | 2.1× | – |
See a number that looks wrong?